Are there any tax implications for subscribing to the Natco Pharma Rights Issue?

Yes, subscribing to Natco Pharma’s right issue has certain tax implications: 1. Subscription: There’s no immediate tax liability. The cost of acquisition is the subscription price plus transaction charges. 2. Capital Gains on Sale: -> Short-Term: Gains from shares sold within 12 months are taxed at 20%. -> Long-Term: Gains from shares held over 12 months are taxed at 12.5% (exceeding ₹1.25 lakh annually). 3. Renunciation: -> Selling rights entitlement attracts capital gains tax. -> Gifted rights have no immediate tax but may impact the recipient later. 4. Dividend Income: Taxed at the shareholder's applicable slab rate. You may consult a tax professional or review the latest tax laws for specific advice.

Natco Pharma Rights Issue

NATCOPHARM

Healthcare Large Cap

839.30.00 (0.00%)

NSE

BSE

Last updated on 25 Sep, 2026 | 15:57 IST

BuySell

Today's High

850.10

Today's Low

834.25

52 Week Low

789.00

52 Week High

1226.80

Free Demat with Zero AMC*

Natco Pharma Right Issue Details

Record Date

01-Oct-2026

Price

₹750

Ratio

2:21

Face Value

2

Natco Pharma has announced a Rights Issue to raise funds. The record date for this issue is 01-Oct-2026, while the issue price has been set at ₹750 per share. The rights ratio stands at 2:21, meaning eligible shareholders will receive the right to apply for additional shares in this proportion to their existing holdings. Each share carries a face value of ₹2.

Upcoming Rights Issue Of Shares

Company	Rights Ratio	Announcement	Record Date	Rights Date
Natco Pharma Ltd.	2:21	09-Sep-2026	01-Oct-2026	01-Oct-2026

Natco Pharma FAQs

The subscription period for Natco Pharma’s rights issue is 09-09-2026 to 01-10-2026. The record date will be 01-10-2026. The subscription window period is usually 15 to 30 days.

As per the ratio of 2:21, the issue price of the shares under Natco Pharma’s right issue on the record date of 01-10-2026 is 750 per equity share.

You can apply for Natco Pharma’s right issue online if your bank supports the Applications Supported by Blocked Amount (ASBA) process.
For offline, Natco Pharma’s Registrar and Transfer Agent (RTA) sends the Composite Application Form (CAF) to each shareholder entitled to receive the Rights Issue. Fill out and submit the form to a Self-Certified Syndicate Bank (SCSB) branch (WEB).
Alternatively, you can use your bank account sharing the same PAN number as your Choice Demat account to apply for Natco Pharma's rights issue.

The record date for Natco Pharma rights issue 2026 is 01-10-2026

The last day to apply for Natco Pharma’s rights issue is 01-10-2026. This date typically falls within a period of 15 to 30 days, from the Rights Issue Opening Date, which in this case is 09-09-2026.

Yes, subscribing to Natco Pharma’s right issue has certain tax implications:

Subscription: There’s no immediate tax liability. The cost of acquisition is the subscription price plus transaction charges.
Capital Gains on Sale:
- Short-Term: Gains from shares sold within 12 months are taxed at 20%.
- Long-Term: Gains from shares held over 12 months are taxed at 12.5% (exceeding ₹1.25 lakh annually).
Renunciation:
- Selling rights entitlement attracts capital gains tax.
- Gifted rights have no immediate tax but may impact the recipient later.
Dividend Income: Taxed at the shareholder's applicable slab rate.

You may consult a tax professional or review the latest tax laws for specific advice.